Drug Type Small molecule drug |
Synonyms Acid Blue 90, BRILLIANT BLUE G, Brilliant blue G (JAN) + [3] |
Target |
Action antagonists |
Mechanism P2X7 receptor antagonists(P2X purinoceptor 7 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (20 Dec 2019), |
RegulationOrphan Drug (United States) |
Molecular FormulaC47H49N3NaO7S2 |
InChIKeyRWFXCYWTHJDCMJ-UHFFFAOYSA-N |
CAS Registry6104-58-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ophthalmologic surgical procedures | United States | 20 Dec 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stress Disorders, Post-Traumatic | Preclinical | China | 01 Dec 2025 | |
Fibrosis | Preclinical | - | - | 01 Apr 2013 |
Nephritis | Preclinical | - | - | 01 Apr 2013 |
Retinal Degeneration | Preclinical | Japan | 01 Apr 2011 |